Lantheus to Present Additional Clinical Data from Phase 3 Pivotal SPLASH Trial in PSMA-Positive Metastatic Castration-Resistant Prostate Cancer During ESMO Congress 2024
Title: Efficacy of 177Lu-PNT2002 in PSMA-positive mCRPC following progression on an androgen-receptor pathway inhibitor (ARPI) (SPLASH)
Presentation Number: LBA65
Lecture Date and Time: Sunday, September 15, 2024, 14:45 (CEST), 8:45 a.m. (EDT)
Room: Valencia Auditorium – Hall 5
Presenter: Oliver Sartor, MD, Director of Radiopharmaceutical Trials and Professor of Medical Oncology at the Mayo Clinic in Rochester, Minnesota
About 177Lu-PNT2002
177Lu-PNT2002 is a PSMA-targeted, lutetium 177-based radioligand therapy candidate that combines a PSMA-targeted ligand, PSMA-I&T, with the beta-emitting radioisotope no-carrier-added lutetium-177. Lantheus in-licensed exclusive worldwide commercialization rights (excluding certain Asian territories) to 177Lu-PNT2002 from POINT Biopharma (a Lilly company) in December of 2022. In April of 2023, the FDA granted Fast Track designation for 177Lu-PNT2002 for the treatment of mCRPC. Fast Track is a process designed to facilitate the development and expedite the review of drugs to treat serious conditions and address unmet medical needs.
Source: Lantheus Holdings, Inc. (2024). Lantheus to Present Additional Clinical Data from Phase 3 Pivotal SPLASH Trial in PSMA-Positive Metastatic Castration-Resistant Prostate Cancer During ESMO Congress 2024 [Press release]. https://investor.lantheus.com/news-releases/news-release-details/lantheus-present-additional-clinical-data-phase-3-pivotal-splash.
Related Content:
PSMAFore, SPLASH and ECLIPSE: Are They Different? "Presentation" - Thomas Hope, Michael Morris, & Oliver Sartor